Full text is available at the source.
Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles
Design of a COVID-19 mRNA Vaccine Targeting the Virus’s Binding Site and Delivered by Fat-Based Particles
AI simplified
Abstract
Intramuscular administration of LNP RBD-hFc mRNA in BALB/c mice elicited a robust humoral response and a high level of neutralizing antibodies.
- Lipid nanoparticles (LNPs) were utilized to encapsulate the SARS-CoV-2 receptor-binding domain.
- Two leading LNP formulations were identified through a luciferase mRNA reporter assay.
- The mRNA vaccine strategy resulted in a Th1-biased cellular response.
- The findings suggest that these lipids could be promising candidates for mRNA vaccines targeting COVID-19.
AI simplified